Cephalon Plans To File Patent Suit Vs Sandoz Over Provigil ANDA

Law360, New York (May 11, 2004, 12:00 AM EDT) -- Cephalon Inc. said in a regulatory filing to the U.S. Securities and Trade Commission that it plans to sue Sandoz Inc. over its Abbreviated New Drug Application (ANDA) for a generic form of modafinil, the active drug substance in its narcolepsy drug Provigil.

Cephalon is in the process of evaluating Sandoz's filing with the Food and Drug Administration and plans shortly to file a patent infringement lawsuit against Sandoz, according to the company’s quarterly filing to the SEC.

Generics drug applicants must include with ANDAs a...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.